Products for Research Use Only
RegisterLogin

Orniplabin

CAT: 0804-HY-122311-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-122311-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin shows potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits ROS[1][2].
CAS Number
733805-92-0
Product Name Alternative
SMTP-7
UNSPSC
12352005
Target
Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/orniplabin.html
Purity
95.0
Solubility
10 mM in DMSO
Smiles
O=C1C2=C(C3=C(C[C@H](O)[C@@](CC/C=C(C)/CC/C=C(C)/C)(C)O3)C(O)=C2)CN1[C@H](C(O)=O)CCCN4CC5=C(C=C(O)C6=C5O[C@](CC/C=C(C)/CC/C=C(C)/C)(C)[C@@H](O)C6)C4=O
Molecular Formula
C51H68N2O10
Molecular Weight
869.09
References & Citations
[1]Shibata K, et al. A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice. Naunyn Schmiedebergs Arch Pharmacol. 2010 Sep;382 (3) :245-53.|[2]Shibata K, et al. Neuroprotective mechanisms of SMTP-7 in cerebral infarction model in mice. Naunyn Schmiedebergs Arch Pharmacol. 2011 Jul;384 (1) :103-8.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
GTR19211161-01Orniplabin

Popular Products